Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis?
BACKGROUND
Calcium dobesilate (CaD) is a member of the synthetic veno-active drug family. Only a small number of reports are available that describe the micro-angiogenic effects of CaD in the current literature.


METHODS
The antiangiogenic potential of CaD was compared with bevacizumab (Bb), which is a potent angiogenesis inhibitor, in a chick chorioallantoic membrane model. Four different concentrations (10-7, 10-6, 10-5, and 10-4 M) of drug pellet were prepared for each drug. Changes in vessel formation were scored and compared for each drug according to the previous literature.


RESULTS
The antiangiogenic behavior of CaD was lower than Bb, despite the significant dose-dependent manner of escalation. The anti-angiogenic scores of CaD were determined as 0.20, 0.47, 0.66, 1.0 in 10-7, 10-6, 10-5, and 10-4 M concentrations, respectively (average score >0.5 was significant).


CONCLUSIONS
According to the data obtained, this agent should be used carefully for cases in which angiogenesis plays an important role in healing.
Department of Cardiovascular Surgery, Medical School of Dicle University, Diyarbakir, Turkey.
Sinan
S
Demirtas
Ahmet
A
Caliskan
Orkut
O
Guclu
Suleyman
S
Yazici
Oguz
O
Karahan
Celal
C
Yavuz
Binali
B
Mavitas
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D002123:Calcium Dobesilate / Q000494:pharmacology / Q000627:therapeutic use*; D002642:Chick Embryo; D055806:Microvessels / Q000187:drug effects / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000150:complications / Q000188:drug therapy*; D016491:Peripheral Vascular Diseases / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002123:Calcium Dobesilate